{4-[(3S,4S)-3-Fluoro-4-pentylcyclohexyl]phenyl}boronic acid

We are {4-[(3S,4S)-3-Fluoro-4-pentylcyclohexyl]phenyl}boronic acid CAS:163006-96-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: {4-[(3S,4S)-3-Fluoro-4-pentylcyclohexyl]phenyl}boronic acid
Other Name:
{4-[(3S,4S)-3-Fluoro-4-pentylcyclohexyl]phenyl}boronic acid
B-[4-[(3S,4S)-3-fluoro-4-pentylcyclohexyl]phenyl]-Boronic acid
B-[2-fluoro-4-(trans-4-pentylcyclohexyl)phenyl]-Boronic acid
[2-Fluoro-4-(trans-4-pentylcyclohexyl)phenyl]boronic acid
CAS No: 163006-96-0
MF: C17H26BFO2
MW: 292.197
Density: 1.1±0.1 g/cm3
Boiling point: 415.7±55.0 °C at 760 mmHg
Melting point: N/A
Flash point: 205.2±31.5 °C
Refractive index: 1.512
UN Number: N/A
Transport hazard class: N/A
Packing group: N/A
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate, OLED intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

{4-[(3S,4S)-3-Fluoro-4-pentylcyclohexyl]phenyl}boronic acid


Related News: We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently.74-93-1 We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently.2-fluoro-6-metilanilina CAS:443-89-0 Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: “Within the top 20 global companies that spent the most on R&D in 2018, the top spender – despite having the second smallest annual revenue of the group at $15.28 billion – is Celgene, whose R&D spend was equal to 37% of its annual revenue.7-chloro-N-(3-chloro-4-fluorophenyl)-6-nitroquinazolin-4-amine At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.

Related Products
Product Name
1,9-Nonanedithiol View Details
2,4,5,6-Tetraaminopyrimidine sulfate View Details
2-Amino-4,6-dimethylpyrimidine View Details
Dipeptide-2 manufacturer 4-amino-5-ethylsulfanyl-2-methoxybenzoic acid manufacturer 2,3-Dihydrobenzo[b]furan-5-carbaldehyde manufacturer dehydroepiandrosterone manufacturer Fmoc-D-Cys(phacm) manufacturer